May 18 is observed as HIV Vaccine Awareness Day globally. As we join the international community to mark this day in Nigeria Positive Action for Treatment Access (PATA), recognizes and thank all the volunteers, community members, health professionals, civil society advocates and scientists involved in HIV vaccine research

This day also presents a unique opportunity to educate communities about the importance of HIV vaccine research.

No doubt there has been much progress in HIV/AIDS research globally. Antiretroviral therapies have contributed to longer and healthier lives for people living with HIV. Pre- exposure prophylaxis has helped to reduce the risk of HIV infection by those not living with HIV.

While these and other preventive tools have the power to reduce the incidence of HIV infection, a safe and effective vaccine would even yield better outcomes. A vaccine would drastically reduce the number of people who become infected and contribute immensely to the global target of ending the AIDS epidemic by 2030.

As effort towards HIV vaccine intensifies in Nigeria, attention should be given to the following:

  • Government at all levels (local, state and federal), should put in place adequate structures and enabling environment to promote vaccine research and development.
  •  Intensive training and retraining of local personnel especially scientists and researchers and exposure to global best practices.
  • Continue on going prevention efforts to reduce new infections, and intensify treatment, care and support services for those infected, while keeping the search for vaccine in focus.
  • Aggressively promote local content in the search for vaccine. The  resolution at the 4th National Council recently held in Abuja, March 19-20, 2018 (Resolution 6:Council approved that the local manufacture of Anti-retroviral (ARV) drugs, Rapid Test Kits (RTKs) and other HIV-related commodities be encouraged (NCA/04/19B) is indeed the way to go with the vaccine initiative in Nigeria.
  • Need for intensive partnership between funders, scientists, advocates and community stakeholders.
  • Community engagement should be given top priority at all stages of the vaccine research and development process.
  • Ensuring ethical standards in trials to ensure we have a vaccine that is “safe, effective, durable, affordable, and accessible.”
  • Mobilization of resources to ensure that the vaccine, when available, gets to the people who need it.
  • Active engagement of people living with HIV and civil society advocates in the research and development process.
  • Massive sensitization as a strategy to address issues of stigma and discrimination. Partnership with the media for effective awareness creation is most desirable.

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas